Merck Stock Holds Steady Amid Oncology Pipeline and Drug Pricing Focus

Merck's stock price has remained relatively stable as of August 31, 2026, trading slightly below $148 per share. The company's oncology pipeline and growth in cornerstone products such as Keytruda, Winrevair, and Welireg in the second quarter of 2026 have garnered attention from investors.

The U.S. drug pricing framework has highlighted Merck's antibody-drug conjugate sacituzumab tirumotecan, which is considered a meaningful asset in the company's oncology portfolio. This development has added qualitative context for Merck's pipeline and growth story underpinning recent gains in the sector.

Recent second-quarter 2026 figures show revenue mix shifts, with Keytruda accounting for 50% of Merck's $16.6 billion in revenue. Strong expansion across other specialty therapies, particularly in rare-disease and cardiovascular segments, has also been noted.